Piramal Pharma Limited Announces Results for Q1FY26

MUMBAI, India, July 28, 2025 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, and health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2025.

 

 

 

Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars

Q1FY26

Q1FY25

YoY Growth

Revenue from Operations

1,934

1,951

(1) %

   CDMO

997

1,057

(6) %

   CHG

637

631

1 %

   PCH

302

263

15 %

EBITDA

165

224

(26) %

EBITDA Margin

9 %

11 %

PAT (after exceptional item)

(82)

(89)

8 %

Key Highlights for Q1FY26

Revenue from Operations stood at ₹ 1,934 crores vs ₹ 1,951 crores in Q1FY25. Excluding the impact of destocking in one of the large CDMO product, the YoY revenue growth was in early double-digit

EBITDA margin at 9% vs 11% in Q1FY25. Impact of inventory destocking, partly offset by improved profitability of the overseas facilities in the CDMO business

Net-Debt to EBITDA ratio at 2.6x

Best-in-Class Quality Track Record – Successfully closed USFDA inspection at Aurora facility (Canada) with zero observations. Continue to maintain our 'Zero OAIs' status since 2011

Sustainability Efforts Yielding Results, Assigned an ESG rating of '61' for FY2024 by NSE Sustainability Ratings and Analytics Limited

Nandini Piramal, Chairperson, Piramal Pharma Limited said, "Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business delivered healthy growth, in-line with our expectations, driven by power brands and e-commerce sales.

Withstanding the near-term challenges, we believe we are on track to achieve our FY2030 aspirations of becoming a US$2bn revenue company with 25% EBITDA margin and high-teen ROCE."

 

Key Business Highlights for Q1 FY2026

Contract Development and Manufacturing Organization (CDMO):

-  Mid-teens growth in base business i.e. excluding ...